The metabolic paradox of aripiprazole: Weight-neutral in monotherapy but weight-reducing as adjunctive therapy

Antipsychotic-induced metabolic dysfunction affects 37–63% of patients, contributing to reduced life expectancy in serious mental illness. Aripiprazole demonstrates a differential effect being weight-neutral in monotherapy but producing substantial weight reduction when combined with clozapine. This is a narrative review of clinical studies examining aripiprazole’s metabolic effects across different treatment contexts, focusing on monotherapy versus adjunctive therapy combinations. Monotherapy studies consistently demonstrate aripiprazole’s weight-neutral profile. However, adjunctive aripiprazole with clozapine produces dramatic weight reduction. Meta-analysis data support adjunctive aripiprazole producing –2.13 kg weight reduction, though effects appear specific to clozapine combinations. This counterintuitive finding may result from aripiprazole’s complex receptor interactions addressing clozapine’s high-affinity H1 and 5-HT2C receptor blockade, restoring metabolic homeostasis while preserving antipsychotic efficacy. Thus, aripiprazole combination transforms clozapine into a more viable long-term treatment by preserving superior antipsychotic efficacy while reversing metabolic dysfunction. Current evidence supports this as standard care for clozapine-treated patients with metabolic complications.